Linfoma no-Hodgkin. Avances en el trasplante autólogo de células madre: Revisión crítica

Translated title of the contribution: Non-Hodgkin's lymphoma. Advances in autologous stem cell transplantation: A critical review

Carlos Montero Osorio, James Olen Armitage

Research output: Contribution to journalReview article

Abstract

The non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality and the trend of this disease is to increase. In the United States of America of 53 900 new cases and 24 400 deaths are estimated in 2002 (1) While patients with aggressive lymphomas can frequently be cured, those with indolent lymphomas, despite a long average survival, have been more difficult to cure. Results indicate that, at least, 40 % to 60 % of patients with NHL eitherfail to achieve a complete remission (CR) or relapse after receiving standard front line therapy. Therefore, the necessity of better treatments is real, particularly in those patients with advanced disease. Data in the field of autologous stem cell transplantation (ASCT) in both groups of patients will be reviewed.

Original languageSpanish
Pages (from-to)16-26
Number of pages11
JournalRevisiones en Cancer
Volume17
Issue number1
StatePublished - Jan 1 2003

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Lymphoma
Neoplasms
Recurrence
Survival
Mortality
Incidence
Therapeutics

Keywords

  • Aggressive lymphomas
  • Autologous
  • Bone marrow transplant
  • High dose therapy
  • Indolent lymphomas
  • Outcome

ASJC Scopus subject areas

  • Oncology

Cite this

Linfoma no-Hodgkin. Avances en el trasplante autólogo de células madre : Revisión crítica. / Montero Osorio, Carlos; Armitage, James Olen.

In: Revisiones en Cancer, Vol. 17, No. 1, 01.01.2003, p. 16-26.

Research output: Contribution to journalReview article

@article{391428ea83994872aac7572fdd37f99d,
title = "Linfoma no-Hodgkin. Avances en el trasplante aut{\'o}logo de c{\'e}lulas madre: Revisi{\'o}n cr{\'i}tica",
abstract = "The non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality and the trend of this disease is to increase. In the United States of America of 53 900 new cases and 24 400 deaths are estimated in 2002 (1) While patients with aggressive lymphomas can frequently be cured, those with indolent lymphomas, despite a long average survival, have been more difficult to cure. Results indicate that, at least, 40 {\%} to 60 {\%} of patients with NHL eitherfail to achieve a complete remission (CR) or relapse after receiving standard front line therapy. Therefore, the necessity of better treatments is real, particularly in those patients with advanced disease. Data in the field of autologous stem cell transplantation (ASCT) in both groups of patients will be reviewed.",
keywords = "Aggressive lymphomas, Autologous, Bone marrow transplant, High dose therapy, Indolent lymphomas, Outcome",
author = "{Montero Osorio}, Carlos and Armitage, {James Olen}",
year = "2003",
month = "1",
day = "1",
language = "Spanish",
volume = "17",
pages = "16--26",
journal = "Revisiones en Cancer",
issn = "0213-8573",
publisher = "ARAN Ediciones S.A.",
number = "1",

}

TY - JOUR

T1 - Linfoma no-Hodgkin. Avances en el trasplante autólogo de células madre

T2 - Revisión crítica

AU - Montero Osorio, Carlos

AU - Armitage, James Olen

PY - 2003/1/1

Y1 - 2003/1/1

N2 - The non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality and the trend of this disease is to increase. In the United States of America of 53 900 new cases and 24 400 deaths are estimated in 2002 (1) While patients with aggressive lymphomas can frequently be cured, those with indolent lymphomas, despite a long average survival, have been more difficult to cure. Results indicate that, at least, 40 % to 60 % of patients with NHL eitherfail to achieve a complete remission (CR) or relapse after receiving standard front line therapy. Therefore, the necessity of better treatments is real, particularly in those patients with advanced disease. Data in the field of autologous stem cell transplantation (ASCT) in both groups of patients will be reviewed.

AB - The non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoid neoplasms that collectively rank fifth in cancer incidence and mortality and the trend of this disease is to increase. In the United States of America of 53 900 new cases and 24 400 deaths are estimated in 2002 (1) While patients with aggressive lymphomas can frequently be cured, those with indolent lymphomas, despite a long average survival, have been more difficult to cure. Results indicate that, at least, 40 % to 60 % of patients with NHL eitherfail to achieve a complete remission (CR) or relapse after receiving standard front line therapy. Therefore, the necessity of better treatments is real, particularly in those patients with advanced disease. Data in the field of autologous stem cell transplantation (ASCT) in both groups of patients will be reviewed.

KW - Aggressive lymphomas

KW - Autologous

KW - Bone marrow transplant

KW - High dose therapy

KW - Indolent lymphomas

KW - Outcome

UR - http://www.scopus.com/inward/record.url?scp=0242668308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0242668308&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:0242668308

VL - 17

SP - 16

EP - 26

JO - Revisiones en Cancer

JF - Revisiones en Cancer

SN - 0213-8573

IS - 1

ER -